Thienopyrimidines are a class of heterocyclic compounds with diverse biological activities depending on their detailed substitution patterns. In addition, many thienopyrimidine derivatives have shown potent activity against cancer cell lines and specific oncogenes.
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study.
Nerandomilast (BI 1015550) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This compound is an investigational agent and has not been approved for use. Nerandomilast was granted FDA Breakthrough Therapy Designation for the treatment of IPF in February 2022.
Buscar 
+86 21 5895 0110 
